Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Platinum), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Latest Videos Types Subtypes The Lymphoma Sessions Conferences Topics Features Podcasts Expert Editorial Board

Welcome to The Lymphoma Channel

VJHemOnc brings you the latest updates in lymphoma, directly from the experts. Alongside our world-leading Editorial Board, The Lymphoma Channel covers all of the latest updates in lymphoma presented at international congresses – including video interviews, podcasts and roundtable discussions.

Dive into The Lymphoma Channel to learn more about the latest advances in therapy, including CAR-T, antibody-drug conjugates, checkpoint inhibitors and targeted therapies. As well as updates in therapy, The Lymphoma Channel also covers the latest research in biomarkers, treating relapsed disease, optimal patient selection and more.

Conferences

iwNHL 2025
SOHO 2025
ICML 2025
EHA 2025
ASCO 2025
iwCAR-T 2025
1:18
Where will trispecific antibodies fit into the lymphoma treatment landscape?
Jason Westin • 28 Sep 2025
1:29
Could trispecific antibodies reduce the need for combination regimens in lymphoma?
Jason Westin • 28 Sep 2025
1:04
Functional differences between trispecific antibodies and bispecific antibodies in lymphoma
Jason Westin • 28 Sep 2025
1:18
The need to refine the definition of nodal-based lymphomas
Laurence de Leval • 27 Sep 2025
View All Videos
8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
0:48
Durability of responses in patients with DLBCL treated with liso-cel: real-world insights
Krish Patel • 4 Sep 2025
1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
View All Videos
4:07
Tracking responses with ctDNA in patients with FL receiving treatment in the LEVERAGE trial
Chan Yoon Cheah • 14 Jun 2025
1:19
Impact of EBV status on outcomes with nivo-AVD versus BV-AVD in patients with Hodgkin lymphoma
Sairah Ahmed • 13 Jun 2025
3:36
The use of BOOM-BOOM radiation prior to liso-cel in aggressive B-cell non-Hodgkin lymphoma
Christopher D'Angelo • 13 Jun 2025
2:51
Key unmet needs in PTCL & the need for more research in this space
Tetiana Skrypets • 20 Jun 2025
View All Videos
1:34
Selecting between glofitamab and epcoritamab for elderly patients with R/R DLBCL
Swetha Thiruvengadam • 10 Jun 2025
1:06
Therapeutic goals in Waldenström’s macroglobulinemia: achieving disease control
Anna Maria Frustaci • 20 Jun 2025
1:42
Long-term follow-up with bispecific antibodies in follicular lymphoma and LBCL
Chan Yoon Cheah • 14 Jun 2025
7:59
The role of therapeutic plasma exchange in managing plasma cell disorders
Danai Dima • 24 Jun 2025
View All Videos
1:10
CAR T-cell therapy for R/R secondary CNS lymphoma: real-world outcomes
Sairah Ahmed • 13 Jun 2025
4:28
Exploring the use of a novel deep learning-based MRI to better identify ICANS after CAR-T
Kathryn Tringale • 12 Jun 2025
0:54
The Phase I/II TITANium trial: AZD5492 in R/R B-cell malignancies
John Kuruvilla • 19 Jun 2025
2:10
Infectious complications of CD20 x CD3 bispecific antibody therapy in patients with B-cell lymphoma
Matthew Matasar • 23 Jun 2025
View All Videos
6:10
Mitigating non-relapse mortality in patients receiving CAR T-cells and bispecifics
Kai Rejeski • 13 Apr 2025
12:30
Strategies to improve the efficacy and minimize the toxicity of CAR T-cell therapy
Elizabeth Buddeet al. • 13 Apr 2025
11:47
Translational insights into T-cell engagers and CAR T-cell therapy: targets, the microbiome, & more
Ciara Freemanet al. • 12 Apr 2025
8:13
CAR T-cells and bispecific antibodies in lymphoma: current perspectives and future considerations
Alexey Danilovet al. • 12 Apr 2025
View All Videos

loretta-nastoupil
Loretta Nastoupil
MD
The University of Texas MD Anderson Cancer Center
tycel-phillips
Tycel Phillips
MD
City of Hope
frederick-locke
Frederick Locke
MD
Moffitt Cancer Center
jessica-okosun
Jessica Okosun
MA, MB BChir, MRCP, FRCPath, PhD
Barts Cancer Institute, Queen Mary University of London
jeremy-abramson
Jeremy Abramson
MD
Massachusetts General Hospital Cancer Center
gloria-iacoboni
Gloria Iacoboni
MD, PhD
Vall d’Hebron Institute of Oncology

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Platinum), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Platinum Supporter

AstraZeneca

Gold Supporter

BMS Johnson & Johnson

Silver Supporter

Takeda

Bronze Supporter

Galapagos

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

The content of VJHemOnc is intended for healthcare professionals